The Health Care Select Sector SPDR Fund (XLV) seeks to track the Health Care Select Sector Index, which measures the performance of healthcare companies within the S&P 500, including pharmaceuticals, biotechnology, medical devices, and healthcare services providers.
How It Works
XLV uses a passively managed, market-capitalization-weighted approach that mirrors the Health Care Select Sector Index. The fund holds all healthcare stocks from the S&P 500 in proportion to their market values, with larger companies like Johnson & Johnson and UnitedHealth receiving higher allocations. Rebalancing occurs quarterly to maintain sector purity and index alignment. The ETF typically holds 60-65 healthcare companies, providing concentrated exposure to this defensive sector.
Key Features
- Pure-play healthcare sector exposure from established S&P 500 companies, avoiding smaller biotech volatility
- Historically defensive characteristics with lower volatility than broader market during economic downturns
- Strong dividend yield of 1.67% from mature pharmaceutical and healthcare service companies
Risks
- This ETF can lose significant value if healthcare regulations change unfavorably or drug pricing faces political pressure
- Concentrated sector exposure means no diversification protection if healthcare underperforms other market sectors substantially
- Individual biotech holdings can decline 20-50% on failed drug trials or FDA rejections, impacting overall returns
Who Should Own This
Best suited as a satellite holding (5-15% of portfolio) for investors with medium risk tolerance seeking defensive sector exposure during economic uncertainty. Appropriate for 3+ year time horizons given healthcare's long development cycles. Works well for income-focused investors wanting sector diversification beyond traditional dividend sectors.